Skip to Main Content

Paper Details

Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
Diabetes Obes Metab
1
2023
Canagliflozin, HbA1c, SGLT2, SLC2A9, SLC5A4, SLC5A9, canagliflozin, creatinine, diabetes, glucose, glucosuria, sodium, sodium-, sodium-glucose, sodium-glucose co-transporter-2, uric acid
Author NameAffiliation
May E MontasserUniversity of Maryland School of Medicine
Braxton D MitchellUniversity of Maryland School of Medicine
Alan R ShuldinerUniversity of Maryland School of Medicine
Alan R ShuldinerUniversity of Maryland School of Medicine
Amber L BeitelsheesUniversity of Maryland School of Medicine
  • 1 - 5

Datasets

Release 1.2